[{"id":"5c09082e-b1b0-4cba-bff1-cce800759223","acronym":"","url":"https://clinicaltrials.gov/study/NCT05103917","created_at":"2021-11-02T17:57:12.570Z","updated_at":"2024-07-02T16:36:21.656Z","phase":"Phase 1/2","brief_title":"A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC","source_id_and_acronym":"NCT05103917","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Xolremdi (mavorixafor)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 24","initiation":"Initiation: 07/21/2021","start_date":" 07/21/2021","primary_txt":" Primary completion: 11/24/2022","primary_completion_date":" 11/24/2022","study_txt":" Completion: 05/21/2023","study_completion_date":" 05/21/2023","last_update_posted":"2021-11-02"}]